

1 **The Impact of Surfactant Protein D, Interleukin-5, and Eosinophilia on**
2 **Cryptococcosis**

3

4 **Stephanie M. Holmer,^a Kathy S. Evans,^b Yohannes G. Asfaw,^d Divey Saini,^e Wiley**
5 **A. Schell,^b Julie G. Ledford,^{a,b} Richard Frothingham,^{b,e} Jo Rae Wright,[†] Gregory D.**
6 **Sempowski,^{b,c,e} and John R. Perfect^{b*}**

7 Departments of Cell Biology,^a Medicine,^b and Pathology,^c Division of Laboratory
8 Animal Resources,^d and Duke Human Vaccine Institute,^e Duke University Medical
9 Center, Durham, North Carolina, USA.

10

11 ***Corresponding author:** John R. Perfect, M.D., Duke University Medical Center,
12 john.perfect@duke.edu

13 [†]Deceased.

14

15 **Running title:** SP-D, IL-5, Eosinophilia and Cryptococcosis

16 **Keywords:** *Cryptococcus neoformans*, Surfactant Protein-D, eosinophils, interleukin-5,
17 pulmonary immunology

18

19 **Abstract**

20 *Cryptococcus neoformans* is an opportunistic fungal pathogen that initiates infection
21 following inhalation. As a result, the pulmonary immune response provides a first line of
22 defense against *C. neoformans*. Surfactant protein D (SP-D) is an important regulator of
23 pulmonary immune responses and is typically host-protective against bacterial and viral
24 respiratory infections. However, SP-D is not protective against *C. neoformans*. This is
25 evidenced by previous work from our laboratory demonstrating that SP-D deficient mice
26 infected with *C. neoformans* have a lower fungal burden and live longer, compared to
27 wild-type (WT) control animals. We hypothesized that SP-D alters susceptibility to *C.*
28 *neoformans* by dysregulating the innate pulmonary immune response following infection.
29 Thus inflammatory cells and cytokines were compared in the bronchoalveolar lavage
30 fluid from WT and SP-D^{-/-} mice after *C. neoformans* infection. Post-infection, mice
31 lacking SP-D have reduced eosinophil infiltration and IL-5 in lung lavage fluid. To
32 further explore the interplay of SP-D, eosinophils, and IL-5, mice expressing altered
33 levels of eosinophils and/or IL-5 were infected with *C. neoformans* to assess the role of
34 these innate immune mediators. IL-5 overexpressing mice have increased pulmonary
35 eosinophilia and are more susceptible to *C. neoformans* infection as compared to WT
36 mice. Furthermore, susceptibility of SP-D^{-/-} mice to *C. neoformans* infection could be
37 restored to that of WT mice by increasing IL-5 and eosinophils, via crossing the IL-5
38 overexpressing mice with SP-D^{-/-} mice. Together, these studies support the conclusion
39 that SP-D increases susceptibility to *C. neoformans* infection by promoting *C.*
40 *neoformans*-driven pulmonary IL-5 and eosinophil infiltration.
41

42 **Introduction**

43

44 *Cryptococcus neoformans* is an opportunistic fungal pathogen of the respiratory tract. It
45 is the leading cause of fungal meningoencephalitis, with one million infections and
46 600,000 attributable deaths occurring annually. *C. neoformans* is especially prevalent in
47 Sub-Saharan Africa where it causes approximately 30% of the deaths of HIV/AIDS
48 victims (1). Because *C. neoformans* is an opportunistic respiratory pathogen, an
49 immune-competent host is generally able to control the infection within the lung.
50 Conversely, when a host becomes immune-compromised the fungi disseminate out of the
51 lung, through the blood, and into the central nervous system (CNS), where uncontrolled
52 growth of cryptococcal organisms typically results in host morbidity and mortality.

53 The nature of the immune response is a critical determinant of host outcome
54 during *C. neoformans* pathogenesis. For example, Th1-skewed immune responses are
55 generally considered host-protective, while Th2-biased immune responses, characterized
56 by high IL-4, IL-5, and eosinophil expression, are non-protective in the context of *C.*
57 *neoformans* infection (2-8). Furthermore, an over-exuberant inflammatory response can
58 lead to complications such as cryptococcal immune reconstitution inflammatory
59 syndrome (IRIS) (9-11). Thus fine-tuned regulation of the inflammatory response is
60 necessary to ensure a favorable outcome for the host against *C. neoformans* infection.

61 Although it has a proclivity for the CNS, *C. neoformans* is a respiratory pathogen
62 that is normally encountered as an aerosol in the environment. Thus cells and proteins of
63 the lung provide the first line of defense against this potentially fatal pathogen. One class
64 of proteins that can regulate immune responses in the lung is surfactant proteins.

65 Although classically known for mediating relief of surface tension in alveolar air spaces,
66 two of the four defined surfactant proteins are now established in the literature as
67 possessing immunomodulatory functions. Specifically, SP-A and SP-D, both members
68 of the collectin family of proteins, are able to interact with pathogens and regulate
69 immune responses. During bacterial and viral infections, as well as allergic reactions,
70 SP-A and SP-D have been extensively shown to play protective roles that benefit the host
71 (reviewed in Ref. (12)).

72 In contradiction to this host-protective paradigm, we have shown that SP-D^{-/-}
73 mice are less susceptible than wild-type (WT) mice to *C. neoformans*, and thus SP-D is
74 considered detrimental to the host during *C. neoformans* infection (13, 14). Our studies
75 have further demonstrated that SP-D^{-/-} mice survive longer and have lower fungal burden
76 than WT control animals. SP-D can opsonize *C. neoformans*, but increased phagocytosis
77 has not been demonstrated to lead to increased fungal death. Instead, SP-D was shown to
78 protect these fungi from macrophage-killing mechanisms, including reactive oxygen
79 species (14). These observations led us to conclude that rather than playing a host-
80 protective role, SP-D facilitates *C. neoformans* pathogenesis by protecting fungi from
81 host immune responses, and that this fungal-protection was, in part, mediated via direct
82 interaction with fungal cells. These findings prompted further *in vivo* investigations into
83 the role of SP-D in mediating cryptococcal pathogenesis.

84 We hypothesized that SP-D exacerbates *C. neoformans* pathogenesis, at least in
85 part, by dysregulating the early pulmonary immune response, causing heightened
86 inflammation and detrimental cellular and cytokine responses. In the present study, using
87 mice with genetically altered levels of IL-5, eosinophils, and SP-D, we examined the role

88 of IL-5 and eosinophil infiltration during *C. neoformans* infection. We concluded that
89 SP-D increases susceptibility to pulmonary *C. neoformans* infection by acting as a natural
90 immune enhancer of infection-driven IL-5 production and eosinophil infiltration in the
91 lung, and that augmented levels of IL-5 and eosinophils contribute to increased host
92 susceptibility to *C. neoformans*.

93 **Materials and Methods**

94

95 **Mice.** All mice were maintained in specific-pathogen free housing at Duke University.
96 SP-D^{-/-} (15) and IL-5Tg^xSP-D^{-/-} and corresponding wild-type (WT) control mice
97 (C57Bl/6J) were bred in-house. IL-5Tg (NJ.1638) (16) mice (kind gift of Dr. James Lee)
98 were also bred in house and WT (C57Bl/6J) littermates were used as controls. As
99 needed, additional C57Bl/6J mice were purchased from Jackson Laboratories (Bar
100 Harbor, ME). For survival studies mice were infected between 6-8 weeks of age. For all
101 other studies, mice were infected between 8-12 weeks of age. Both males and females
102 were used. The animal protocol was approved by the Institutional Animal Care and Use
103 Committee of Duke University (Protocol Number: A021-12-01). All surgery was
104 performed under anesthesia with ketamine and xylazine, and every effort was made to
105 minimize pain and suffering.

106

107 ***C. neoformans* strains.** Mice were infected with H99 Stud, a highly virulent strain of *C.*
108 *neoformans* serotype A that was created by passaging a mixed stock of *C. neoformans*,
109 which included H99#1 (the original human isolate generated by Dr. John Perfect) through
110 a rabbit (17). H99 Stud was used because of its effective and reproducible pathogenicity.
111 H99 Stud was stored in a glycerol stock at -80°C. H99 Stud was maintained on yeast
112 extract-peptone-dextrose (YPD) agar for up to one month. Liquid cultures were grown
113 for 8 to 18 hours at 30°C with shaking (~250 rpm).

114

115 ***C. neoformans* infection.** For aerosol exposures, H99 Stud was grown at 30°C overnight
116 in YPD liquid medium, then subcultured (1:100) for a second night, and inoculated onto
117 V8 agar plates (made with 5% V8 original tomato juice, pH 5.0) in 10 µL spots (about 50
118 spots/plate) for 2-3 weeks. On the day of exposure, fungal colonies were gently removed
119 with a cell scraper, dispersed into sterile PBS, centrifuged, and resuspended to 1×10^8
120 cells/mL in sterile deionized water. *C. neoformans* was aerosolized using a 6-jet
121 Collision nebulizer (CN25, BGI Incorporated). Mice were exposed to H99 Stud aerosol
122 in a whole-body Madison chamber for 60 minutes at 95% relative humidity, in a BSL-3
123 biocontainment facility (NIAID Regional Biocontainment Laboratory at Duke). After
124 exposure, mice were handled in class III and class II biosafety cabinets connected to the
125 Madison chamber. They were then kept in hermetically sealed cages. Aerosol
126 concentration of *C. neoformans* was measured via a BioSampler (SKC Incorporated)
127 attached to the Madison chamber as previously described (18).

128 For intranasal instillation, H99 Stud was prepared as previously described (14).
129 Briefly, *C. neoformans* cells were washed in sterile saline three times, counted, and
130 resuspended to the desired cell density (between 5×10^4 and 5×10^5 yeast cells per mouse in
131 25-50 µL of saline as specified below). Mice were sedated with a ketamine (Ketaset®,
132 Fort Dodge) (150 mg/kg) and xylazine (Anased®, Lloyd Incorporated) (10 mg/kg)
133 mixture and hung gently by their incisors on a taut thread. The cell suspension was
134 delivered by careful pipetting into one nostril. Sham-infected mice were given an
135 equivalent volume of sterile saline. The mice were allowed to hang for five minutes after
136 *C. neoformans* instillation.

137 For fungal burden studies, histological analysis, survival studies, and flow
138 cytometric analysis, mice were instilled with 5×10^4 *C. neoformans* cells in 25-50 μ L
139 saline. For survival studies, mice were monitored for weight loss and general health per
140 approved IACUC protocol. When mice lost more than 15% of initial body weight or
141 became moribund they were humanely euthanized according to approved IACUC
142 protocol. For BAL cellularity and cytokine analysis, mice were instilled with a higher
143 dose of 5×10^5 H99 Stud cells as a higher dose elicited greater differences in immune
144 responses of WT and SP-D^{-/-} mice.

145

146 **BAL cellularity and cytokine analysis.** On the day of organ harvest, mice were
147 euthanized with Nembutol® (Oak Pharmaceuticals) or Euthasol® (Virbac Corporation)
148 and exsanguinated via the renal artery. Lungs were perfused with a sufficient volume of
149 sterile PBS to flush RBCs (5-10 mL) and then lavaged with 0.1 mM EDTA in PBS. A
150 total of 6 mL lavage fluid was collected in 1 mL aliquots. BAL cells were centrifuged at
151 350 x g. Supernatant from the first 1 mL was stored at -80°C for cytokine analysis. BAL
152 cells for each sample were pooled, counted, and adhered to slides via centrifuging 200 μ L
153 BAL in a Cytospin 2 (Shandon Incorporated) in at 400 rpm for 4 minutes. 50-100,000
154 cells were used for each cytopsin. Cytospins were air dried, fixed with methanol, and
155 stained with hematoxylin and eosin (H&E) for differential counting.

156 Cytokine concentrations were measured in cell-free supernatants acquired from
157 the first 1 mL of collected BAL by multiplex assay using the 20-plex mouse
158 inflammatory cytokine and chemokine panel (Invitrogen Life Sciences). For some
159 experiments, IL-5 levels were assessed via ELISA (BD Biosciences: Pharmingen).

160 Control samples showed comparable results for IL-5 concentration in both the bead-
161 based multiplex and the ELISA assays.

162

163 **Fungal burden analysis.** On the day of harvest, mice were euthanized and
164 exsanguinated as described above. For fungal burden analysis, lung tissue was excised
165 and homogenized, and samples were diluted and plated onto YPD agar plates and
166 incubated at room temperature or 30°C until colonies became large enough to count
167 (usually 48-72 hours).

168

169 **Tissue histology.** Histological analyses were performed similarly to those previously
170 described (19). Lungs were gravity inflated with 10% neutral buffered formalin (NBF),
171 and paraffin embedded. 4-5um sections were deparaffinized and stained with
172 hematoxylin and eosin. Blinded samples were scored by a veterinary pathologist for
173 necrosis, hemorrhage, edema, *Cryptococcus*, and inflammation. Scores ranged from 0 to
174 8 with the score roughly representing the percentage of tissue involved (0 = 0%, 1 = 10%,
175 2 = 20%, etc.).

176

177 **Lung tissue digests and immunophenotyping by flow cytometry.** Lung digests for
178 immunophenotyping were performed similarly to previously described methods (20).
179 After perfusing and collecting BAL, the whole lung was excised and finely chopped with
180 razor blades in a petri dish. Lung tissue was diluted in 4.5 mL HBSS with Ca²⁺ and Mg²⁺
181 and digested with DNase I and Collagenase XI (Roche). Single-cell suspensions were
182 attained by passing the digested material through 40 um strainers and cells of

183 hematopoietic-lineage were enriched by centrifuging the samples in a 4%/14.5%
184 iodixanol gradient (Optiprep®; Axis-Shield). Cells were stained with the following
185 antibodies: FITC Gr-1 (clone RB6-8C5; BD Biosciences), PE-Cy5.5 CD11c (clone
186 N418; eBiosciences), APC-CD11b (clone M1/70; eBiosciences), Biotin MHC II (clone
187 2G9; BD Biosciences), and PE-Cy7 CD45 (clone 30-F11; BD Biosciences). PE-Texas
188 Red Streptavidin (BD Biosciences) was used as the conjugate for biotin-labeled
189 antibodies. Finally, cells were fixed with 10% NBF.

190 Immunophenotype list mode data were acquired on a BD-LSR II (BD
191 Biosciences). Using Flow software (Treestar), sample data (FCS 3.0) were first analyzed
192 for FSC-H versus FSC-A to gate on single cells. CD45⁺ hematopoietic-lineage cells were
193 then analyzed for Gr-1, CD11c, and MHC class II expression using bi-variate dot plots.
194 PMNs were defined as Gr-1^{hi}CD11c^{neg-lo} cells. We also assessed CD11c⁺MHCII^{int} cells
195 (which should mainly consist of macrophages) and CD11c⁺MHCII^{hi} cells (which should
196 mainly consist of dendritic cells). This gating strategy is based on the work of Lin, *et al.*
197 (21). Cells that were Gr-1^{neg-lo} CD11c^{neg-lo}MHC II^{neg-lo} with high SSC were considered to
198 be eosinophils (22, 23). The phenotype of these cells was confirmed by FACS and
199 cytospin analysis with H&E staining. The remaining CD45⁺ cells were designated
200 “lymphocytes/other”. Isotype-matched antibodies were used for control staining.

201

202 **RNA isolation, reverse transcription (RT), and real-time PCR analysis.** RNA was
203 isolated from lung tissue with TRIzol reagent (Invitrogen) per manufacturer’s protocol,
204 followed by chloroform extraction and isopropanol precipitation. Equal amounts of RNA
205 were reverse-transcribed with MMLV and random primers. Real-time PCR was

206 performed with the double-stranded DNA probe SYBR green in a two-step reaction on a
207 Bio-Rad CFX96 machine. Results were normalized to β -actin RNA as an internal control
208 and analyzed by the $2^{-\Delta\Delta CT}$ method. The oligonucleotide primers for β -actin were 5'-
209 GATTACTGCTCTGGCTCCTAG-3' (Forward) and 5'-
210 GACTCATCGTACTCCTGCTTGC-3' (Reverse). The oligonucleotide primers for IL-5
211 were 5'-AGCACAGTGGTGAAAGAGACCTT-3' (Forward) and 5'-
212 TCCAATGCATAGCTGGTGATTT-3' (Reverse).

213

214 **Statistical analysis.** Statistical analyses were performed with GraphPad Prism software
215 (version 5.0) or SAS Statview software. To compare two groups, data were analyzed by
216 two-tailed Student's T test. For multiple comparisons, data were analyzed by one-way or
217 two-way ANOVA followed by Bonferroni's or Tukey's posttest correction. Survival
218 studies were assessed via Kaplan-Meier survival curve analysis with the Mantel-Cox test.
219 A *P*-value of < 0.05 was considered significant.

220

221 **Results**

222

223 **SP-D^{-/-} mice are less susceptible than WT mice to *C. neoformans* in an aerosol**

224 **exposure model.** SP-D is a constitutively expressed pulmonary protein that is
225 immediately available to interact with *C. neoformans* after the pathogen enters the lung.
226 Our previous studies used intranasal instillation of inoculum by directly pipetting a
227 suspension of cryptococcal cells into the nostrils of lightly sedated mice. Naturally
228 occurring *C. neoformans* infections, however, generally arise after inhalation of
229 aerosolized *C. neoformans* in the environment. Thus, we asked whether a more natural
230 route of exposure to *C. neoformans* would yield comparable results to intranasal
231 instillation; that is, whether SP-D would facilitate *C. neoformans* pathogenesis after
232 exposure to aerosolized fungal cells.

233 WT and SP-D^{-/-} mice were simultaneously exposed to aerosolized *C. neoformans*
234 in a Madison whole-body exposure chamber (see materials and methods). The average
235 aerosol concentration of three independent exposures was 8±2 CFU/mL. The fungal load
236 was quantified at 1 hour, 24 hours, 10 days, 14 days, and 21 days post-infection. At early
237 stages of infection (1 hour and 24 hours), WT and SP-D^{-/-} mice had similar fungal loads,
238 but as the infection progressed fungal loads were higher in WT mice compared to SP-D^{-/-}
239 mice with a significant difference between strains apparent at 14 and 21 days post-
240 infection (Figure 1A). Histological analysis at day 21-post-infection confirmed increased
241 pathology in WT mice compared to SP-D^{-/-} mice (Figure 1B-C and Table 1). These data
242 corroborate that SP-D facilitates *C. neoformans* pathogenesis across different models of

243 infection and support the continued use of the more accessible intranasal instillation
244 method as a model infection route for *C. neoformans* in mice.

245 **SP-D^{-/-} mice have a decreased pulmonary cellular immune response to *C.***
246 ***neoformans* compared to WT mice.** To further characterize the effect of SP-D during
247 *C. neoformans* infection, the pulmonary cellular response in WT and SP-D^{-/-} mice was
248 assessed. Using immunophenotyping and polychromatic flow cytometry, myeloid cell
249 infiltration in both BAL and interstitial lung tissue was quantified at three and seven days
250 post-*C. neoformans* infection. In lung interstitium and BAL, the absolute number of
251 infiltrating CD45⁺ cells (hematopoietic lineage cells) in both WT and SP-D^{-/-} mice
252 increased with infection (Figure 2A-B). This CD45⁺ cell lung infiltration was
253 statistically lower in infected SP-D^{-/-} mice than in infected WT control mice. A similar
254 trend was observed in BAL. Detailed analysis of the frequency of myeloid cell
255 populations within the lung CD45⁺ compartment revealed that the difference between
256 infected WT and SP-D^{-/-} mice could not be accounted for by differences in the proportion
257 of polymorphonuclear cells (PMNs) (Figure 2C-D), CD11c⁺MHCII^{int} cells (likely
258 macrophages) (Figure 2E-F), nor CD11c⁺MHCII^{hi} cells (likely dendritic cells) (Figure
259 2G-H). However, a large population of MHC II^{neg-low}/CD11c^{neg-low}/SSC^{hi} cells was
260 observed that was lower in infected SP-D^{-/-} mice than in infected WT mice (data not
261 shown). Since this population of cells was undetermined by our flow cytometry panels,
262 additional cytospin analysis with H&E staining was conducted and revealed that these
263 cells were eosinophils (Figure 3E-H). Thus, eosinophils account for the majority of the
264 CD45⁺ pulmonary cell influx post-*C. neoformans* infection and SP-D^{-/-} mice had reduced
265 frequencies of eosinophil infiltration compared to WT mice. SP-D^{-/-} mice also had lower

266 absolute numbers of eosinophils after seven days of *C. neoformans* infection compared to
267 WT mice in the interstitium ($24 \times 10^5 \pm 5 \times 10^5$ cells in WT mice and $5 \times 10^5 \pm 1 \times 10^5$ cells in
268 SP-D^{-/-} mice) and BAL ($9 \times 10^5 \pm 3 \times 10^5$ cells in WT mice and $7 \times 10^5 \pm 3 \times 10^5$ cells in SP-D^{-/-}
269 mice), which further endorsed the substantial differences between WT and SP-D^{-/-} mice.
270 WT and SP-D^{-/-} mice did not have significantly different frequencies of the remainder of
271 CD45⁺ cells, which were primarily lymphocytes.

272 To confirm the findings of the flow cytometric analysis, eosinophils were
273 quantified by classical cytopsin/histologic analysis of BAL cells. Eosinophils were
274 significantly lower in infected SP-D^{-/-} mice compared to infected WT mice at day seven
275 (Figure 3A). The resultant eosinophilia values were lower by cytopsin analysis than they
276 were by FACS analysis: this is because the design of the flow cytometry panel tends to
277 underestimate the number of eosinophils. Notably, the fold differences were similar
278 using both methods (*i.e.* WT mice had more eosinophils than SP-D^{-/-} mice, post
279 infection). Thus, we concluded that eosinophils dominate the lung environment after *C.*
280 *neoformans* infection and that SP-D enhances eosinophilia during *C. neoformans*
281 infection in both the interstitial and alveolar compartments of the lung.

283 **SP-D^{-/-} mice have altered pulmonary cytokine/chemokine responses to *C.***

284 ***neoformans* compared to WT mice.** To determine the effect of SP-D on the lung
285 inflammatory cytokine response to *C. neoformans*, we quantified levels of twenty
286 cytokines in BAL fluid from WT and SP-D^{-/-} mice seven days post-infection (Table 2).

287 In WT mice, *C. neoformans* infection stimulated higher production of IFN- γ , TNF- α , IL-
288 4, IL-5, IL-6, IL-12, IL-13, IP-10, and MCP-1 compared to sham-infected WT mice. Of

289 these infection-induced cytokines/chemokines, IFN- γ , IL-4, IL-6, and IL-13 were
290 produced at comparable levels in SP-D^{-/-} mice, suggesting that SP-D does not alter the
291 production of these immune mediators seven days post-*C. neoformans* infection.

292 Of interest, IL-5, IP-10, and MCP-1 were significantly higher in SP-D^{-/-} mice
293 compared to WT mice after seven days of infection, revealing a possible mechanism by
294 which SP-D protein may cause suppression of some cytokines/chemokines during *C.*
295 *neoformans* infection. Additionally, *C. neoformans* infection stimulated production of
296 MIG and MIP-1 α specifically in SP-D^{-/-} mice. Since neither was detected in WT mice,
297 this finding suggests that SP-D suppresses certain host cytokine/chemokine responses in
298 fungal infection. Conversely, *C. neoformans* infection stimulated TNF- α production in
299 WT mice significantly more than in SP-D^{-/-} mice, showing that SP-D might enhance
300 TNF- α expression. IL-17, KC, GM-CSF, IL-1 α , IL-1 β , IL-2, and IL-10 were not induced
301 by *C. neoformans* infection (data not shown for GM-CSF, IL-1 α , IL-1 β , IL-2, and IL-10).
302 Overall, cytokine/chemokine analysis did not reveal a clear bias toward Th1 or Th2
303 responses; rather SP-D has a dysregulating, sometimes stimulating and sometimes
304 suppressing, effect on certain chemokines and Th1 cytokines seven days post-infection.

305 Interestingly, higher IL-5 levels in SP-D^{-/-} mice compared to WT mice seven days
306 post-infection was incongruent with our cellular analyses showing higher eosinophilia in
307 WT mice. We postulated that there were earlier increases in IL-5 that could account for
308 the elevated eosinophilia observed at seven days post-infection. Thus IL-5 levels were
309 quantified three days post-infection in both strains of mice. As predicted, BAL IL-5 was
310 highly induced in WT mice three days post-infection compared to SP-D^{-/-} mice (Figure
311 3B). This early rise in lung IL-5 protein levels in WT mice corresponded with increased

312 IL-5 steady-state mRNA levels in lung tissue of WT mice during day two post-infection
313 (Figure 3C). This early induction of IL-5 expression levels was not detected in SP-D^{-/-}
314 mice. Additionally, it should be noted that multiplex analysis was performed at day
315 three for the same cytokine panel as day seven, and we did not observe any significant
316 differences that seemed as relevant to eosinophilia as the results with IL-5 (data not
317 shown).

318 To determine whether IL-5 was necessary for the observed eosinophil recruitment
319 in this model, IL-5 neutralizing antibodies were administered by i.p. injection on the day
320 of infection and eosinophilia was measured seven days post-infection (Figure 3D).
321 Eosinophilia induced by *C. neoformans* infection was drastically reduced in both WT and
322 SP-D^{-/-} mice with antibody administration, thus affirming the critical importance of IL-5
323 for eosinophil recruitment during acute *C. neoformans* infection. Together these data
324 demonstrate that delayed IL-5 induction accounts for decreased eosinophilia in SP-D^{-/-}
325 mice as compared to WT mice.

326

327 **Mice overexpressing IL-5 and eosinophils are more susceptible to *C. neoformans***
328 **than WT mice.** Having established that IL-5 and eosinophil levels are augmented more
329 in WT mice than SP-D^{-/-} mice during the early phase of infection, it was next necessary to
330 define the role of IL-5 and eosinophils during cryptococcal pathogenesis in relationship
331 to SP-D. Thus IL-5 Transgenic (Tg) mice that overproduce IL-5 under a T cell specific
332 promoter and therefore have a constitutive overabundance of eosinophils in the peripheral
333 blood were infected with 5x10⁴ H99 Stud cells for histological studies, pulmonary fungal
334 burden comparisons, and survival analyses (16). As predicted, after *C. neoformans*

335 infection, IL-5Tg mice displayed high overexpression of both IL-5 and eosinophils in
336 BAL fluid (Figure S1). At seven days post-infection, fungal burden was significantly
337 higher in IL-5Tg mice (Figure 4A). Histological analysis confirmed the fungal burden
338 analysis and revealed that IL-5Tg mice had increased necrosis and inflammation
339 compared to WT mice (Table 3 and Figure 6). Finally, IL-5Tg mice died more rapidly in
340 survival studies compared to WT control mice (Figure 4B). These data indicated that
341 augmentation of IL-5 production and resulting eosinophilia contributed significantly to *C.*
342 *neoformans* pathogenesis.

343

344 **IL-5 overexpression reverses the SP-D^{-/-} response to *C. neoformans*.** We next
345 examined the *in vivo* linkage between IL-5 and SP-D by asking whether augmenting IL-5
346 levels in SP-D deficient mice could reverse the SP-D^{-/-} phenotype and result in increased
347 susceptibility to *C. neoformans* infection. We created IL-5TgxSP-D^{-/-} mice and assessed
348 fungal burden, histology, and survival in these mice. Cytokine and cytospin analysis
349 confirmed high levels of eosinophils and IL-5 seven days post-infection in IL-5TgxSP-D^{-/-}
350 ^{-/-} mice (Figure S1). At fourteen days post-infection, IL-5TgxSP-D^{-/-} mice had higher
351 than SP-D^{-/-} mice, and lower than IL-5Tg mice similar fungal burden to WT mice (Figure
352 5A). Survival analysis, likewise, revealed that IL-5TgxSP-D^{-/-} mice were significantly
353 more susceptible to *C. neoformans* than SP-D^{-/-} mice, less susceptible than IL-5Tg mice,
354 and not statistically different from WT mice (Figure 5B). Histological analysis
355 confirmed that IL-5TgxSP-D^{-/-} mice were less susceptible to *C. neoformans* than IL-5Tg
356 mice as they had lower levels of hemorrhage, necrosis, edema, cryptococcal cells, and
357 inflammation (Table 3 and Figure 6). Together, these data demonstrated that

358 overexpression of IL-5, and thus eosinophils, restores SP-D^{-/-} mice to the WT phenotype
359 and supports the conclusion that SP-D protein augments *C. neoformans* disease in the
360 murine host by promoting an excessive IL-5 expression and eosinophil infiltration in
361 response to this fungal infection.

362 **Discussion**

363

364 SP-D is well documented as a host-protective immunoregulatory protein, yet our
365 previous studies have demonstrated that SP-D fails to protect mice against *C. neoformans*
366 by promoting fungal growth and survival to the detriment of the host (13, 14). The
367 uniqueness of the interaction between SP-D and *C. neoformans* prompted further
368 investigation into the mechanisms by which SP-D affects host outcome in the face of *C.*
369 *neoformans* infection. Because of the immunoregulatory role of SP-D, we hypothesized
370 that one mechanism by which SP-D increases susceptibility to *C. neoformans* may be
371 through dysregulation of host immune responses. Analysis of *C. neoformans* infection in
372 WT and SP-D^{-/-} mice revealed that SP-D increases inflammatory cell infiltrate and
373 dysregulates the balance of pulmonary cytokines in response to *C. neoformans*. We
374 specifically identified a role for SP-D in augmenting eosinophils and IL-5, an eosinophil
375 recruitment and survival cytokine, during active *C. neoformans* infection. Select mutant
376 mouse models were used to further examine the roles of IL-5, eosinophils, and SP-D
377 during *C. neoformans* pathogenesis. Together these studies demonstrate a dynamic
378 interplay between SP-D, IL-5, and eosinophils in determining the outcome of *C.*
379 *neoformans* disease during the critical early phase of pulmonary infection.

380 To mimic the natural route of infection, we examined the ability of SP-D to
381 facilitate cryptococcal pathogenesis after exposure to aerosolized *C. neoformans* cells.
382 WT mice were more susceptible to aerosol exposures of *C. neoformans* than SP-D^{-/-} mice
383 (Figure 1). This confirmed that the ability of SP-D to affect *C. neoformans* disease is free
384 of artifact due to the intranasal instillation method, corroborating our previous survival

385 and fungal burden analyses with intranasal infections and firmly establishing that SP-D
386 increases susceptibility to *C. neoformans* infection (13). This conclusion is further
387 supported by models using inducible SP-D mice and via rescue studies in which SP-D
388 protein instilled in the nostrils of SP-D^{-/-} mice increased susceptibility of SP-D^{-/-} mice to
389 the levels of WT mice (13). These findings clearly validate the intranasal instillation
390 method as a biologically relevant and robust model for early pulmonary *C. neoformans*
391 disease and, thus, in the immunological studies that followed, we used the traditional and
392 more readily accessible intranasal method.

393 Immunophenotyping revealed *C. neoformans* induced higher levels of
394 inflammatory (CD45⁺) cells in WT mice compared to SP-D^{-/-} mice (Figure 2), indicating
395 that SP-D contributes to *C. neoformans* pathogenesis by exacerbating over-exuberant
396 immune responses that might be detrimental to the host. This was in agreement with our
397 hypothesis. Furthermore, the presence of SP-D in WT mice was associated with
398 increased eosinophil recruitment (Figure 3). This is in direct contrast with the mold,
399 *Aspergillus fumigatus*, a medically relevant fungal species that has been studied
400 extensively in the context of SP-D, in which the main role of SP-D is to suppress
401 excessive inflammation, including eosinophilia, thereby reducing damage to the host (24-
402 28). Thus, we postulate that while SP-D protects against *A. fumigatus* by dampening and
403 thus preventing over-exuberant immune responses and excessive eosinophilia after *A.*
404 *fumigatus* exposure, it conversely contributes to *C. neoformans* pathogenesis by
405 augmenting eosinophilic responses to *C. neoformans* leading to excessive inflammation
406 and potentially damaging the surrounding host tissue. The histology from this study and

407 from previous studies support this hypothesis (13), as WT mice displayed more extensive
408 damage within the pulmonary airspaces than SP-D^{-/-} mice (Figure 1 and Table 1).

409 In addition to analysis of the cellular immune response, we also examined
410 cytokine/chemokine responses after *C. neoformans* infection. Multiple pro-inflammatory
411 markers were induced by *C. neoformans* infection in both WT and SP-D^{-/-} mice, with
412 several key chemokines and Th1 cytokines expressed to a lesser extent in WT mice
413 (Table 2). These observations indicate that SP-D may contribute to the susceptibility of
414 WT mice by suppressing key inflammatory cytokines and chemokines, such as IL-12, IP-
415 10, MIP-1 α , MIG, and MCP-1, which are normally protective against *C. neoformans* (4-6,
416 29-34).

417 Following the immune phenotyping observations of eosinophil differences in the
418 lung interstitial and lavage compartments, specific examination of IL-5 levels showed
419 delayed IL-5 induction in SP-D^{-/-} compared to WT mice (Figure 3 and Table 2). These
420 data revealed a dynamic role for SP-D in modulating IL-5 expression and we postulated
421 that a delayed IL-5 response in SP-D^{-/-} mice resulted in decreased eosinophilia as
422 detected seven days after infection. Furthermore, IL-5 blockade studies presented herein
423 confirm that IL-5 is required for eosinophilia at an early stage of acute infection. This is
424 in accordance with previous work in which IL-5 was also necessary for eosinophilia in a
425 chronic *C. neoformans* infection model (8). During chronic *C. neoformans* infection,
426 CD4⁺ T cells were critical producers of IL-5, but we expect that other cell types are a
427 more significant source of IL-5 during the initial stages of an acute response. Potential
428 candidates include lung stromal cells, such as epithelial cells (35, 36), and innate immune

429 cells, such as mast cells, monocytes, or a newly identified IL-5 producing non-T
430 lymphoid cell type that can rapidly produce this cytokine (37-40).

431 The role of IL-5 and eosinophils during *C. neoformans* pathogenesis has remained
432 elusive. Along with the widely published fact that eosinophilia has often been associated
433 with ineffective immune responses against *C. neoformans*, it has been shown that
434 eosinophils bind *C. neoformans* in the presence of opsonizing antibodies (41), late phase
435 *C. neoformans*-induced pulmonary eosinophilia is IL-5 dependent (8), and eosinophils
436 have *C. neoformans*-derived antigen presenting capabilities (42, 43). Recently
437 eosinophils were found to be important producers of IL-4, and thus are contributors to
438 non-protective Th2 responses (44). It has remained unclear whether IL-5 and eosinophils
439 are mere bystanders during an otherwise pathogenic Th2 process or whether they were
440 active contributors to *C. neoformans* disease. The present studies help to elucidate the
441 role of eosinophils and IL-5 in *C. neoformans* pathogenesis in the context of SP-D.
442 Overexpression of IL-5 and a large resultant eosinophil population significantly increased
443 host susceptibility to *C. neoformans* (Figure 4). This is in contrast with recent bacterial
444 studies that demonstrated that IL-5Tg mice were protected against bacterial infection due
445 to bactericidal capabilities of eosinophils (45). Furthermore, studies with IL-5Tg \times SP-D $^{-/-}$
446 mice determined that augmenting expression of IL-5 and eosinophils in SP-D $^{-/-}$ mice was
447 sufficient to restore susceptibility to *C. neoformans*, providing strong evidence that
448 decreased IL-5 and eosinophils are an important part of explaining the mechanistic role
449 of SP-D in promoting *C. neoformans* pathogenesis (Figure 5). However, we did examine
450 whether components of these interactions had an impact on the phenotype. When fungal
451 burden and survival were additionally assessed in PHIL (eosinophil-deficient) and IL5 $^{-/-}$

452 mice after *C. neoformans* infection (data not shown) we found no or minimal impact,
453 respectively, on outcome. Taken together, these data suggest that IL-5, eosinophils, and
454 SP-D work together to determine host fate in *C. neoformans* disease and highlight the
455 importance of balance in host cytokine production, collectin presence, and host cell influx
456 to the site of infection during specific microbial assaults.

457 In the present study, SP-D acts as a natural enhancer of *C. neoformans*-driven IL-
458 5 production and eosinophil infiltration in the lung, leading to increased host
459 susceptibility. This model is in contrast to *A. fumigatus* (24-27, 46) in which SP-D plays
460 a host-protective role by reducing Th2 responses. The ability of SP-D to act as a
461 suppressor of IL-5 and eosinophilia in *A. fumigatus* models, while acting as an enhancer
462 of IL-5 and eosinophilia during *C. neoformans* infection can be explained by the dual role
463 of SP-D in inflammation. SP-D can act as an anti-inflammatory molecule when present
464 as a dodecamer that interacts with SIRP α . Conversely, SP-D can act as a pro-
465 inflammatory molecule leading to NF- κ B activation and proinflammatory signaling
466 cascades after *S*-nitrosylation, trimer formation and interaction with CD91/calreticulin
467 (47). Previous work showing that oligomeric SP-D inhibits eosinophil chemotaxis, while
468 *S*-nitrosylated SP-D does not, supports this dual role paradigm for SP-D in eosinophilia
469 (48, 49). Future studies should focus on gaining a deeper understanding of the dual role
470 of SP-D in infection and inflammation by examining the oligomeric structure and post-
471 translational modifications of SP-D during both *C. neoformans* and *A. fumigatus*
472 infections. Although both are pathogenic fungi, they diverge widely in nucleic acid
473 sequence, morphology, pathogenic features, and host susceptibility. Comparing the
474 status of SP-D protein in both models should lend significant insight into fundamental

475 differences about how SP-D differentially affects host outcome in the face of two
476 divergent types of fungal infections.

477 In conclusion, the effects of SP-D, IL-5, and eosinophils are interwoven to
478 establish the early innate immune response to this encapsulated yeast and promote fungal
479 pathogenesis. Future studies focused on disrupting the interactions of this triad of factors
480 could suggest potential therapeutic strategies leading to disease prevention.

481

482 **Acknowledgements**

483 This work was supported by Public Health Service grants R01-HL30923 to J.R.W. and
484 R01-AI73896 to J.R.P from the National Institutes of Health.

485 The authors would like to thank Julia L. Nugent, Kristina Riebe, and Melissa
486 Ventevogel for technical assistance, particularly with breeding, genotyping, and handling
487 mice. We also thank Ching-Ju Chen, Sarah Seay, and Rosemarie Asrican for technical
488 assistance with aerobiology studies, and Patrice McDermott for technical assistance with
489 flow cytometry studies.

490 Aerosol challenges, flow cytometry, and cytokine profiling were performed in the
491 NIAID Regional Biocontainment Laboratory at Duke (UC6-AI058607, U54-AI057157,
492 P30-AI051445) by the Duke Human Vaccine Institute (DHVI) Aerobiology Shared
493 Resource Facility, the DHVI Flow Cytometry Shared Resource Facility under the
494 direction of John F. Whitesides, and the DHVI Immune Reconstitution & Biomarker
495 Analysis Shared Resource Facility, respectively.

496

497

498 **References**

- 499 1. **Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller**
500 **TM.** 2009. Estimation of the current global burden of cryptococcal meningitis
501 among persons living with HIV/AIDS. *AIDS* **23**:525-530.
- 502 2. **Jain AV, Zhang Y, Fields WB, McNamara DA, Choe MY, Chen Gh, Erb-**
503 **Downward J, Osterholzer JJ, Toews GB, Huffnagle GB, Olszewski MA.**
504 2009. Th2 but Not Th1 Immune Bias Results in Altered Lung Functions in a
505 Murine Model of Pulmonary *Cryptococcus neoformans* Infection. *Infection and*
506 *Immunity* **77**:5389-5399.
- 507 3. **Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, Schutze N,**
508 **Straubinger RK, Blessing M, McKenzie AN, Brombacher F, Alber G.** 2007.
509 IL-13 induces disease-promoting type 2 cytokines, alternatively activated
510 macrophages and allergic inflammation during pulmonary infection of mice with
511 *Cryptococcus neoformans*. *J Immunol* **179**:5367-5377.
- 512 4. **Hardison SE, Ravi S, Wozniak KL, Young ML, Olszewski MA, Wormley FL,**
513 **Jr.** 2010. Pulmonary infection with an interferon-gamma-producing *Cryptococcus*
514 *neoformans* strain results in classical macrophage activation and protection. *Am J*
515 *Pathol* **176**:774-785.
- 516 5. **Chen Gh, McNamara DA, Hernandez Y, Huffnagle GB, Toews GB,**
517 **Olszewski MA.** 2008. Inheritance of Immune Polarization Patterns Is Linked to
518 Resistance versus Susceptibility to *Cryptococcus neoformans* in a Mouse Model.
519 *Infection and Immunity* **76**:2379-2391.

- 520 6. **Zhang Y, Wang F, Tompkins KC, McNamara A, Jain AV, Moore BB, Toews**
521 **GB, Huffnagle GB, Olszewski MA.** 2009. Robust Th1 and Th17 Immunity
522 Supports Pulmonary Clearance but Cannot Prevent Systemic Dissemination of
523 Highly Virulent *Cryptococcus neoformans* H99. American Journal Of Pathology
524 **175:2489-2500.**
- 525 7. **Wozniak KL, Ravi S, Macias S, Young ML, Olszewski MA, Steele C,**
526 **Wormley FL.** 2009. Insights into the mechanisms of protective immunity against
527 *Cryptococcus neoformans* infection using a mouse model of pulmonary
528 cryptococcosis. PLoS One **4:e6854.**
- 529 8. **Huffnagle GB, Boyd MB, Street NE, Lipscomb MF.** 1998. IL-5 is required for
530 eosinophil recruitment, crystal deposition, and mononuclear cell recruitment
531 during a pulmonary *Cryptococcus neoformans* infection in genetically susceptible
532 mice (C57BL/6). J Immunol **160:2393-2400.**
- 533 9. **Wiesner DL, Boulware DR.** 2011. Cryptococcus-Related Immune
534 Reconstitution Inflammatory Syndrome(IRIS): Pathogenesis and Its Clinical
535 Implications. Current fungal infection reports **5:252-261.**
- 536 10. **da Cunha Colombo ER, Mora DJ, Silva-Vergara ML.** 2011. Immune
537 reconstitution inflammatory syndrome (IRIS) associated with *Cryptococcus*
538 *neoformans* infection in AIDS patients. Mycoses **54:e178-182.**
- 539 11. **Skiest DJ, Hester LJ, Hardy RD.** 2005. Cryptococcal immune reconstitution
540 inflammatory syndrome: report of four cases in three patients and review of the
541 literature. The Journal of infection **51:e289-297.**

- 542 12. **Crouch EC.** 1998. Collectins and pulmonary host defense. *Am J Respir Cell Mol*
543 *Biol* **19**:177-201.
- 544 13. **Geunes-Boyer S, Beers MF, Perfect JR, Heitman J, Wright JR.** 2012.
545 Surfactant Protein D Facilitates *Cryptococcus neoformans* Infection. *Infect*
546 *Immun* **80**:2444-2453.
- 547 14. **Geunes-Boyer S, Oliver TN, Janbon G, Lodge JK, Heitman J, Perfect JR,**
548 **Wright JR.** 2009. Surfactant Protein D Increases Phagocytosis of Hypocapsular
549 *Cryptococcus neoformans* by Murine Macrophages and Enhances Fungal
550 Survival. *Infection and Immunity* **77**:2783-2794.
- 551 15. **Korfhagen TR, Sheftelyevich V, Burhans MS, Bruno MD, Ross GF, Wert**
552 **SE, Stahlman MT, Jobe AH, Ikegami M, Whitsett JA, Fisher JH.** 1998.
553 Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. *J Biol*
554 *Chem* **273**:28438-28443.
- 555 16. **Lee NA, McGarry MP, Larson KA, Horton MA, Kristensen AB, Lee JJ.**
556 1997. Expression of IL-5 in thymocytes/T cells leads to the development of a
557 massive eosinophilia, extramedullary eosinophilopoiesis, and unique
558 histopathologies. *J Immunol* **158**:1332-1344.
- 559 17. **Morrow CA, Lee IR, Chow EW, Ormerod KL, Goldinger A, Byrnes EJ, 3rd,**
560 **Nielsen K, Heitman J, Schirra HJ, Fraser JA.** 2012. A unique chromosomal
561 rearrangement in the *Cryptococcus neoformans* var. *grubii* type strain enhances
562 key phenotypes associated with virulence. *MBio* **3**.
- 563 18. **Saini D, Hopkins GW, Chen CJ, Seay SA, Click EM, Lee S, Hartings JM,**
564 **Frothingham R.** 2011. Sampling port for real-time analysis of bioaerosol in

- 565 whole body exposure system for animal aerosol model development. Journal of
566 pharmacological and toxicological methods **63**:143-149.
- 567 19. **Steinbach WJ, Benjamin DK, Jr., Trasi SA, Miller JL, Schell WA, Zaas AK,**
568 **Foster WM, Perfect JR.** 2004. Value of an inhalational model of invasive
569 aspergillosis. *Med Mycol* **42**:417-425.
- 570 20. **Awasthi S.** 2010. Surfactant protein (SP)-A and SP-D as antimicrobial and
571 immunotherapeutic agents. *Recent Pat Antiinfect Drug Discov* **5**:115-123.
- 572 21. **Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD.** 2008. CCR2+
573 monocyte-derived dendritic cells and exudate macrophages produce influenza-
574 induced pulmonary immune pathology and mortality. *J Immunol* **180**:2562-2572.
- 575 22. **Rose S, Misharin A, Perlman H.** 2012. A novel Ly6C/Ly6G-based strategy to
576 analyze the mouse splenic myeloid compartment. *Cytometry. Part A : the journal*
577 *of the International Society for Analytical Cytology* **81**:343-350.
- 578 23. **Milam JE, Herring-Palmer AC, Pandrangi R, McDonald RA, Huffnagle GB,**
579 **Toews GB.** 2007. Modulation of the pulmonary type 2 T-cell response to
580 *Cryptococcus neoformans* by intratracheal delivery of a tumor necrosis factor
581 alpha-expressing adenoviral vector. *Infect Immun* **75**:4951-4958.
- 582 24. **Kishore U, Madan T, Sarma PU, Singh M, Urban BC, Reid KBM.** 2002.
583 Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung
584 allergy and infection caused by *Aspergillus fumigatus*. *Immunobiology* **205**:610-
585 618.

- 586 25. **Madan T, Kishore U, Singh M, Strong P, Hussain EM, Reid KBM, Sarma**
587 **PU.** 2001. Protective Role of Lung Surfactant Protein D in a Murine Model of
588 Invasive Pulmonary Aspergillosis. *Infection and Immunity* **69**:2728-2731.
- 589 26. **Madan T, Reid KB, Clark H, Singh M, Nayak A, Sarma PU, Hawgood S,**
590 **Kishore U.** 2010. Susceptibility of mice genetically deficient in SP-A or SP-D
591 gene to invasive pulmonary aspergillosis. *Mol Immunol* **47**:1923-1930.
- 592 27. **Madan T, Reid KB, Singh M, Sarma PU, Kishore U.** 2005. Susceptibility of
593 mice genetically deficient in the surfactant protein (SP)-A or SP-D gene to
594 pulmonary hypersensitivity induced by antigens and allergens of *Aspergillus*
595 *fumigatus*. *J Immunol* **174**:6943-6954.
- 596 28. **Brandt E, Mingler M, Stevenson M, Wang N, Khuranahershey G, Whitsett**
597 **J, Rothenberg M.** 2008. Surfactant protein D alters allergic lung responses in
598 mice and human subjects. *Journal of Allergy and Clinical Immunology* **121**:1140-
599 1147.e1142.
- 600 29. **Olszewski MA, Huffnagle GB, Traynor TR, McDonald RA, Cook DN, Toews**
601 **GB.** 2001. Regulatory effects of macrophage inflammatory protein 1alpha/CCL3
602 on the development of immunity to *Cryptococcus neoformans* depend on
603 expression of early inflammatory cytokines. *Infect Immun* **69**:6256-6263.
- 604 30. **Olszewski MA, Huffnagle GB, McDonald RA, Lindell DM, Moore BB, Cook**
605 **DN, Toews GB.** 2000. The role of macrophage inflammatory protein-1
606 alpha/CCL3 in regulation of T cell-mediated immunity to *Cryptococcus*
607 *neoformans* infection. *J Immunol* **165**:6429-6436.

- 608 31. **Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL,**
609 **Jr.** 2012. Protective immunity against pulmonary cryptococcosis is associated
610 with STAT1-mediated classical macrophage activation. *J Immunol* **189**:4060-
611 4068.
- 612 32. **Huffnagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD,**
613 **Kunkel SL, Toews GB.** 1995. The role of monocyte chemotactic protein-1
614 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary
615 *Cryptococcus neoformans* infection. *J Immunol* **155**:4790-4797.
- 616 33. **Vecchiarelli A, Pietrella D, Bistoni F, Kozel TR, Casadevall A.** 2002.
617 Antibody to *Cryptococcus neoformans* capsular glucuronoxylomannan promotes
618 expression of interleukin-12Rbeta2 subunit on human T cells in vitro through
619 effects mediated by antigen-presenting cells. *Immunology* **106**:267-272.
- 620 34. **Wormley FL, Perfect JR, Steele C, Cox GM.** 2007. Protection against
621 Cryptococcosis by Using a Murine Gamma Interferon-Producing *Cryptococcus*
622 *neoformans* Strain. *Infection and Immunity* **75**:1453-1462.
- 623 35. **Salvi S, Semper A, Blomberg A, Holloway J, Jaffar Z, Papi A, Teran L,**
624 **Polosa R, Kelly F, Sandstrom T, Holgate S, Frew A.** 1999. Interleukin-5
625 production by human airway epithelial cells. *Am J Respir Cell Mol Biol* **20**:984-
626 991.
- 627 36. **Wu CA, Peluso JJ, Zhu L, Lingenheld EG, Walker ST, Puddington L.** 2010.
628 Bronchial epithelial cells produce IL-5: implications for local immune responses
629 in the airways. *Cell Immunol* **264**:32-41.

- 630 37. **Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S,**
631 **Hattori Y, Kouro T, Itakura A, Nagai Y, Takaki S, Takatsu K.** 2012.
632 Identification of innate IL-5-producing cells and their role in lung eosinophil
633 regulation and antitumor immunity. *J Immunol* **188**:703-713.
- 634 38. **Plaut M, Pierce JH, Watson CJ, Hanley-Hyde J, Nordan RP, Paul WE.** 1989.
635 Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI
636 or to calcium ionophores. *Nature* **339**:64-67.
- 637 39. **Okayama Y, Kobayashi H, Ashman LK, Holgate ST, Church MK, Mori M.**
638 1997. Activation of eosinophils with cytokines produced by lung mast cells. *Int*
639 *Arch Allergy Immunol* **114 Suppl 1**:75-77.
- 640 40. **Diedrich CR, Mattila JT, Flynn JL.** 2013. Monocyte-Derived IL-5 Reduces
641 TNF Production by Mycobacterium tuberculosis-specific CD4 T Cells during
642 SIV/M. tuberculosis Coinfection. *J Immunol* **190**:6320-6328.
- 643 41. **Feldmesser M, Casadevall A, Kress Y, Spira G, Orlofsky A.** 1997. Eosinophil-
644 *Cryptococcus neoformans* interactions in vivo and in vitro. *Infect Immun*
645 **65**:1899-1907.
- 646 42. **Garro AP, Chiapello LS, Baronetti JL, Masih DT.** 2011. Eosinophils elicit
647 proliferation of naive and fungal-specific cells in vivo so enhancing a T helper
648 type 1 cytokine profile in favour of a protective immune response against
649 *Cryptococcus neoformans* infection. *Immunology* **134**:198-213.
- 650 43. **Garro AP, Chiapello LS, Baronetti JL, Masih DT.** 2010. Rat eosinophils
651 stimulate the expansion of *Cryptococcus neoformans*-specific CD4(+) and
652 CD8(+) T cells with a T-helper 1 profile. *Immunology*.

- 653 44. **Piehler D, Stenzel W, Grahnert A, Held J, Richter L, Kohler G, Richter T,**
654 **Eschke M, Alber G, Muller U.** 2011. Eosinophils contribute to IL-4 production
655 and shape the T-helper cytokine profile and inflammatory response in pulmonary
656 cryptococcosis. *Am J Pathol* **179**:733-744.
- 657 45. **Linch SN, Kelly AM, Danielson ET, Pero R, Lee JJ, Gold JA.** 2009. Mouse
658 eosinophils possess potent antibacterial properties in vivo. *Infect Immun* **77**:4976-
659 4982.
- 660 46. **Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, Martin C, Baelder R, Glaab T,**
661 **Braun A, Steinhilber W, Luettig B, Uhlig S, Hoymann HG, Krug N, Hohlfeld**
662 **JM.** 2006. Surfactant protein D inhibits early airway response in *Aspergillus*
663 *fumigatus*-sensitized mice. *Clin Exp Allergy* **36**:930-940.
- 664 47. **Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE,**
665 **Henson PM.** 2003. By binding SIRPalpha or calreticulin/CD91, lung collectins
666 act as dual function surveillance molecules to suppress or enhance inflammation.
667 *Cell* **115**:13-23.
- 668 48. **Atochina-Vasserman EN, Winkler C, Abramova H, Schaumann F, Krug N,**
669 **Gow AJ, Beers MF, Hohlfeld JM.** 2011. Segmental allergen challenge alters
670 multimeric structure and function of surfactant protein D in humans. *Am J Respir*
671 *Crit Care Med* **183**:856-864.
- 672 49. **von Bredow C, Hartl D, Schmid K, Schabaz F, Brack E, Reinhardt D, Griese**
673 **M.** 2006. Surfactant protein D regulates chemotaxis and degranulation of human
674 eosinophils. *Clin Exp Allergy* **36**:1566-1574.
- 675

677 **Figure Legends**

678

679 **Figure 1.** SP-D^{-/-} mice are more resistant than WT mice to aerosol exposure of *C.*
680 *neoformans*. (A) Mice were exposed to aerosolized H99 Stud in full-body Madison
681 chambers and fungal burden was assessed in the lung up to 21 days post-infection. Each
682 time point was repeated at least twice for a total n of 7-8 mice/group. Representative
683 images from histological analyses of paraffin-embedded and H&E-stained lung tissue
684 from (B) WT mice, and (C) SP-D^{-/-} mice after aerosol exposure. * P < 0.05, ** P < 0.01.

685

686 **Figure 2.** Total CD45⁺ cells are decreased in SP-D^{-/-} mice compared to WT mice after *C.*
687 *neoformans* infection. Flow cytometric analysis of total CD45⁺ cells in WT and SP-D^{-/-}
688 mice after *C. neoformans* infection in (A) lung interstitium (Day 3: n = 5-9 mice/group;
689 Day 7: n = 14-21 mice/group), and (B) lung BAL (Day 3: n = 1-2 samples/group; Day 7:
690 n = 5-8 samples/group; samples were pooled and normalized to per mouse cell counts).
691 Shown in Panels A and B are absolute numbers of cells per mouse calculated from total
692 cellularity obtained and the percentage of CD45⁺ cells. Frequency of PMNs in lung
693 interstitium (C) and BAL (D), CD11c⁺MHCII^{int} cells in lung interstitium (E) and BAL
694 (F), CD11c⁺MHCII^{hi} cells in lung interstitium (G) and BAL (H), and lymphocytes / other
695 CD45⁺ cells in lung interstitium (I) and BAL (J). In Panels C-J, data are shown as
696 percentages of CD45⁺ cells. * P < 0.05 for WT infected vs. SP-D^{-/-} infected mice
697 comparison.

698

699 **Figure 3.** IL-5 production and eosinophil infiltration are reduced in infected SP-D^{-/-} mice
700 compared to WT mice. WT and SP-D^{-/-} mice were infected intranasally with 5x10⁵ H99
701 Stud cells. (A) Eosinophils in BAL were assessed seven days post-infection via cytopsin
702 and H&E staining (n = 3-11 mice/group). (B) IL-5 protein levels were measured three
703 days post-infection in BAL fluid by ELISA (n = 8-10 mice/group). (C) IL-5 mRNA
704 steady-state level was measured on days 1-3 post-infection in post-lavaged lung tissue (n
705 = 4-10 mice/group). (D) Mice were administered IL-5 neutralizing antibodies at the time
706 of infection. Eosinophils were assessed in BAL seven days post-infection via cytopsin
707 and H&E staining. For the IL-5 blockade, data are shown as frequency of the respective
708 isotype-treated control (n = 12-14 mice/group). * P < 0.05, ** P < 0.01, *** P < 0.001.
709 Photomicrographs show representative cytopsin used for analysis of: (E) saline-treated
710 WT mice, (F) saline-treated SP-D^{-/-} mice, (G) *C. neoformans*-infected WT mice, and (H)
711 *C. neoformans*-infected SP-D^{-/-} mice. Arrowheads indicate macrophages and arrows
712 indicate eosinophils.

713

714 **Figure 4.** IL-5 overexpressing mice are more susceptible to *C. neoformans* than WT
715 mice. (A) Pulmonary fungal burden at seven days post-*C. neoformans* infection in WT
716 and IL-5Tg. *** P < 0.001. (B) Survival analysis of WT and IL-5Tg mice (two
717 independent experiments for a total n of at least 18 mice/group; P < 0.0001).

718

719

720

721 **Figure 5.** IL-5 overexpression increases the susceptibility of SP-D^{-/-} mice to *C.*
 722 *neoformans*. (A) Pulmonary fungal burden at fourteen days post-*C. neoformans* infection
 723 in WT, IL-5Tg, SP-D^{-/-}, and IL-5TgxSP-D^{-/-} mice. * P < 0.05, ** P < 0.01, *** P < 0.001.
 724 (B) Survival analysis of WT, IL-5Tg, SP-D^{-/-}, and IL-5TgxSP-D^{-/-} mice (two independent
 725 experiments for a total n of at least 3 mice/group; P values: WT vs. SP-D^{-/-} < 0.001; WT
 726 vs. IL-5TgxSP-D^{-/-} = NS; IL-5TgxSP-D^{-/-} vs. SP-D^{-/-} < 0.05; and IL-5TgxSP-D^{-/-} vs. IL-
 727 5Tg < 0.001.)

728

729 **Figure 6.** Representative photomicrographs from H&E-stained lung sections seven days
 730 after *C. neoformans* infection: (A) WT sham-infected mice, (B) WT *C. neoformans*-
 731 infected mice, (C) SP-D^{-/-} sham-infected mice, (D) SP-D^{-/-} *C. neoformans*-infected mice,
 732 (E) IL-5Tg sham-infected mice, (F) IL-5Tg *C. neoformans*-infected mice, (G) IL-
 733 5TgxSP-D^{-/-} sham-infected mice, and (H) IL-5TgxSP-D^{-/-} *C. neoformans*-infected mice.
 734 Arrows indicated *C. neoformans* cells; the cell wall of *C. neoformans* is stained by
 735 hematoxylin.

736

737 **Tables**

738

739 **TABLE 1: Histological analysis of H&E-stained lung sections 21 days post-aerosol**
 740 **challenge.^{a,b}**

Genotype	Necrosis	Hemorrhage	Edema	Cryptococcus	Inflammation	Composite
WT	2.7	1.3	1	7.7	6.7	19.3
SP-D ^{-/-}	3	1.7	0.3	3.7	4	12.7

741 ^a Data are expressed as means; N = 2-5 mice/group.

742 ^b Sham-infected WT and SP-D^{-/-} mice received a score of 0 for each category.

743

744

745 **TABLE 2: Levels of BAL cytokines and chemokines (pg/mL) 7 days post-infection^a**

Cytokine	WT Control	SP-D ^{-/-} Control	WT Infected	SP-D ^{-/-} Infected	WT Fold Change	SP-D ^{-/-} Fold Change
IFN- γ	9.2(0.1)	12(2)	50(10) ^b	49(8) ^b	6.0 ^c	4.2
TNF- α	10.1(0.5)	10.1(0.5)	20(3) ^b	16(2) ^{b,c}	2.0	1.6
IL-4	16.2(0.3)	16.1(0.3)	110(20) ^b	160(20) ^b	7.0	9.8
IL-5	9.3(0.07)	9.3(0.07)	310(40) ^b	550(70) ^{b,c}	33.8 ^c	59.2
IL-6	14(1)	14(1)	130(20) ^b	200(30) ^b	9.4	13.9
IL-12	9(2)	40(8) ^d	60(8) ^b	81(7) ^b	6.7 ^c	2.0
IL-13	17(2)	17(2)	800(80) ^b	800(200) ^b	47.1 ^c	49.1
IL-17	5(1)	5(1)	7.4(0.6)	9(1) ^b	1.4	1.6
IP-10	8(2)	7(2)	57(6) ^b	140(10) ^{b,c}	7.3 ^c	18.8
MCP-1	19(2)	24(5)	300(30) ^b	530(50) ^{b,c}	16.0	22.2
MIG	5(2)	7(3)	29(6)	42(9) ^b	5.5	6.4
MIP-1 α	27(8)	29(7)	120(20)	190(40) ^b	4.6	6.7
VEGF	90(10)	160(10) ^d	30(8) ^b	50(20) ^b	0.4	0.3
FGF basic	40(9)	90(20)	100(20)	170(30)	2.5	1.9
KC	180(60)	230(50)	94(5)	130(40)	0.6	0.6

746 ^a Concentrations are expressed as Mean(SE); N = 10-15 mice/group; data accumulated
 747 from 3-4 independent experiments.

748 ^b Infected mice are significantly different than respective saline-treated control mice.

749 ^c Infected SP-D^{-/-} are significantly different than infected WT mice.

750 ^d Baseline SP-D^{-/-} mice are significantly different than baseline WT mice.

751 ^e Fold change is significantly different in WT and SP-D^{-/-} mice.

752

753 **TABLE 3: Histological analysis of H&E-stained lung sections 7 days post-**
 754 **infection^{a,b}**

Genotype	Necrosis	Hemorrhage	Edema	<i>Cryptococcus</i>	Inflammation	Composite
WT	2.3	1.3	0.8	4.3	4.0	12.8
SP-D^{-/-}	1.4	1.0	0.0	3.6	2.6	8.6
IL-5Tg	3.3	2.3	1.6	6.5	5.8	19.4
IL-5Tg x SP-D^{-/-}	1.7	1.0	0.7	3.0	3.0	9.3

755 ^a Data are expressed as means; N = 2-5 mice/group.

756 ^b All sham-infected mice received a score of 0 for each category except IL-5Tg mice,
 757 which received a mean score of 0.3 for inflammation and IL-5TgxSP-D^{-/-} mice, which
 758 received a mean score of 0.5 for hemorrhage and 1 for inflammation.











